Citizens JMP raised the firm’s price target on Enanta (ENTA) to $25 from $24 and keeps an Outperform rating on the shares. Enanta Pharmaceuticals ...

NORTH CHICAGO, Ill., June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET® (glecaprevir ...

Mavyret approved to treat acute hepatitis C in patients, with or without cirrhosis. Eight-week treatment shows 96% cure rate with mostly mild side effects. Tim Melvin’s system has spotted 10X ...

Mavyret is available as 100mg/40mg fixed-dose tablets in a 4-week (monthly) or 8-week carton. Each carton contains 7 daily dose wallets. For more information visit abbvie.com.

AbbVie Inc.’s newly approved drug Mavyret can treat hepatitis C’s six major strains in eight weeks. It’s also a positive steal in the hepatitis C drug world, at $26,400 for a eight-week ...

AbbVie's Mavyret will likely gain 15%-20% of the global HCV market by 2019. Gilead's HCV revenue will likely decline $1B-1.5B per year starting in 2019.

AbbVie's Mavyret is the first eight-week treatment that has been approved by the U.S. FDA for all the 1-6 known genotypes of the hepatitis C-Virus in non-cirrhotic HCV patients, who are naive to ...

This photo provided by AbbVie shows the drug Mavyret. On Thursday, Aug. 3, 2017, the Food and Drug Administration approved Mavyret to treat all forms of hepatitis C. The drug works in as little as ...

Approval of Mavyret tablets has been expanded to eight-week treatment for treatment-naive patients with chronic hepatitis C and compensated cirrhosis, the U.S. Food and Drug Administration announced.

"MAVYRET has treated more than one million patients with HCV, but we recognize that a significant need remains for patients with acute infection," said Roopal Thakkar, M.D., executive vice ...